COMPARING THE EFFECT OF AN AROMATASE INHIBITOR (LETROZOL) plus CABERGOLINE AND LETROZOL ALONE ON UTERINE MYOMA REGRESSION

被引：0
|
作者：
Sayyah-Melli, M. [1 ]
Rahmani, V. [2 ]
Mobasseri, M. [2 ]
机构：
[1] Tabriz Univ Med Sci, Womens Reprod Hlth Res Ctr, Ob & Gyn, Tabriz, Iran
[2] Tabriz Univ Med Sci, Ob & Gyn, Tabriz, Iran
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS-0089
引用
收藏
页码：951 / 951
页数：1
相关论文
共 37 条
  • [21] Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2-advanced breast cancer in Chinese clinical practice: a real-world study
    Yue, Jian
    Wang, Xue
    Ju, Jie
    Yang, Zixiang
    Wei, Tong
    Yuan, Peng
    Gao, Min
    Xu, Ling
    Guan, Yin
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2-metastatic breast cancer: A SEER-Medicare analysis
    Brufsky, Adam
    Sandin, Rickard
    Stergiopoulos, Stella
    Chen, Connie
    Karanth, Siddharth
    Li, Benjamin
    Esterberg, Lizzi
    Makari, Doris
    Candrilli, Sean D.
    Goyal, Ravi K.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER plus breast cancer (BC) patients: A POETIC study (CRUK/07/015)
    Gao, Q.
    Lopez-Knowles, E.
    Cheang, M. C. U.
    Morden, J.
    Martin, L-A
    Sidhu, K.
    Evans, D.
    Martins, V.
    Dodson, A.
    Skene, A.
    Holcombe, C.
    Mallon, E.
    Abigail, E.
    Bliss, J.
    Robertson, J.
    Smith, I.
    Dowsett, M.
    CANCER RESEARCH, 2017, 77
  • [24] EXpANd study:: A prospective, open, randomised, two armed clinical phase IV-studies for examination of the effect of Letrozol (Femara®) alone or in combination with Zoledronic acid (Zometa®) as "Erweiterte adjuvante Therapie" (extended adjuvant treatment)post-menopausal female patients with primary breast carcinoma (CFEM345DDE09, Eudract-Nr. 2004-003888-71)
    Hellriegel, M.
    Dickewied, C.
    Emons, G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2007, 67 (08) : 914 - 914
  • [25] Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial A randomized clinical trial of neoadjuvant therapy for ESCC
    Li, Yong
    Zhou, Aiping
    Liu, Shuoyan
    He, Ming
    Chen, Keneng
    Tian, Ziqiang
    Li, Yin
    Qin, Jianjun
    Wang, Zhen
    Chen, Haiquan
    Tian, Hui
    Yu, Yue
    Qu, Wang
    Xue, Liyan
    He, Shun
    Wang, Shuhang
    Bie, Fenglong
    Bai, Guangyu
    Zhou, Bolun
    Yang, Zhaoyang
    Huang, Huiyao
    Fang, Yan
    Li, Benjamin
    Dai, Xiangrong
    Gao, Shugeng
    He, Jie
    BMC MEDICINE, 2023, 21 (01)
  • [26] Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trialA randomized clinical trial of neoadjuvant therapy for ESCC
    Yong Li
    Aiping Zhou
    Shuoyan Liu
    Ming He
    Keneng Chen
    Ziqiang Tian
    Yin Li
    Jianjun Qin
    Zhen Wang
    Haiquan Chen
    Hui Tian
    Yue Yu
    Wang Qu
    Liyan Xue
    Shun He
    Shuhang Wang
    Fenglong Bie
    Guangyu Bai
    Bolun Zhou
    Zhaoyang Yang
    Huiyao Huang
    Yan Fang
    Benjamin Li
    Xiangrong Dai
    Shugeng Gao
    Jie He
    BMC Medicine, 21
  • [27] Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2-early breast cancer (EBC)
    Fasching, P. A.
    Slamon, D.
    Nowecki, Z.
    Kukielka-Budny, B. D.
    Stroyakovskiy, D.
    Yardley, D.
    Huang, C.
    Chan, A.
    Chia, S.
    Martin, M.
    Rugo, H. S.
    Loi, S.
    Hurvitz, S. A.
    Untch, M.
    Afenjar, K.
    Fresco, R.
    Danyliv, A.
    Ferrusi, I.
    Li, Z.
    Hortobagyi, G. N.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 951 - 953
  • [28] Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses
    Halmos, Balazs
    Pennell, Nathan A.
    Otterson, Gregory Alan
    Gadgeel, Shirish M.
    Mekhail, Tarek
    Snell, Michael Robert
    Kuebler, J. Phillip
    Fu, Pingfu
    Sharma, Neelesh
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Comparing Tamoxifen (TAM) Plus Everolimus (RAD) With TAM Alone in Patients With Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) With Prior Exposure to Aromatase Inhibitors (AIs): Implication for Research Strategies
    Bourgier, C.
    Ray-Coquard, I.
    Provencal, J.
    Cropet, C.
    Bourcier, A. V.
    Delecroix, V.
    Reynaud-Bougnoux, A.
    Cretin, J.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S331 - S331
  • [30] Comparing the effect of STan (cardiotocographic electronic fetal monitoring (CTG) plus analysis of the ST segment of the fetal electrocardiogram) with CTG alone on emergency caesarean section rates: study protocol for the STan Australian Randomised controlled Trial (START)
    Turnbull, D.
    Salter, A.
    Simpson, B.
    Mol, B. W.
    Chandraharan, E.
    McPhee, A.
    Symonds, I
    Benton, M.
    Kuah, S.
    Matthews, G.
    Howard, K.
    Wilkinson, C.
    TRIALS, 2019, 20 (01)
1234